Loading patent…
AssigneeUniversity of Louisville Research Foundation, Inc.
InventorsRamesh C. Gupta, Radha Munagala, Farrukh Aqil, Jeyaprakash Jeyabalan
Estimating the term…
A composition is provided that comprises a therapeutic agent encapsulated by a milk-derived microvesicle. The compositions can include therapeutic agents such as phytochemical agents or chemotherapeutic agents, while the milk-derived microvesicle can be derived from raw milk or colostrum. Further provided are methods for isolating a microvesicle that includes the steps of obtaining an amount of milk, and subjecting the milk to a series of sequential centrifugations configured to yield greater than about 300 mg of microvesicle protein per 100 ml of milk. Methods of modifying an immune response and treating a cancer in which a milk-derived microvesicle composition is administered are also provided.
A composition, comprising an effective amount of a therapeutic agent encapsulated by a milk-derived microvesicle, wherein the therapeutic agent is a chemotherapeutic agent selected from, taxane compounds, anti-tumor vinca alkaloids, anti-tumor anthracycline derivatives, HER2 antibodies, DNA methyl transferase inhibitors, actinomycin D, adriamycin, capecitabine, carboplatin, cisplatin, daunorubicin, doxorubicin, 5-fluorouracil, gemcitabine, idarubicin, mitoxantrone, oxaliplatin, retinoids, retinoic acid metabolism blocking agents (RAMBA), taxol, vinblastine, vincristine, vinorelbine, vitamin D, Accutane, and combinations thereof.
A composition, comprising a therapeutic agent encapsulated by a milk-derived microvesicle, wherein the milk-derived microvesicle is isolated by obtaining an amount of milk and subjecting the milk to a first centrifugation at 20,000×g at 4° C. for 30 min, and then a second centrifugation at 100,000×g at 4° C. for 60 min, and then a third centrifugation at 120,000×g at 4° C. for 90 min, such that a yield greater than about 50 mg of microvesicle protein per 100 ml of milk is recovered, and wherein the therapeutic agent is a chemotherapeutic agent selected from doxorubicin, paclitaxel, docetaxel, and combinations thereof.
Dependencies are inferred from the claim text.